SABA1 is an antibacterial agent against Pseudomonas aeruginosa and Escherichia coli. It functions by inhibiting biotin carboxylase (BC), an enzyme that catalyzes the first half-reaction of acetyl-CoA carboxylase (ACC), which is essential for fatty acid synthesis in bacteria. Notably, SABA1 exhibits an atypical inhibition mechanism by binding to the biotin binding site of BC in the presence of ADP. This unique mode of action positions SABA1 as a promising candidate in the development of new antibiotics, especially crucial in the face of rising antimicrobial resistance.